Confirmation of Helicobacter pylori eradication using ¹³C urea breath test: addressing the regional post-treatment outcomes Authors: Dinesh Muthuluru, Sonit Bhusan Patanik, Pukhraj Singh Jeji, Akash Dobhada, Kanishka Uthansingh, Manoj Kumar Sahu Published: 2025 ABSTRACT AbstractBackgroundAs a major etiological factor of the gastrointestinal diseases, the presence of Helicobacter pylori (H. pylori) poses a serious concern to the clinical management; however, the confirmation of the eradication post-therapy is of utmost crucial. The purpose of this study was to use the 13C Urea Breath Test (UBT) in measuring the effectiveness of second-line quadruple therapy in assessing treatment failure due to the infection with resistant strains of H. pylori, particularly in the state of Odisha.MethodsThe study included 70 adult patients (mean age 42.5 ± 12.7 years) with H. pylori infection who participated in first-line eradication therapy. The 13C UBT was performed approximately 50.4 ± 14.4 days after therapy to determine the eradication success. Patients who have tested positive in the initial treatment were subjected to second-line quadruple therapy. The collected data in a designed proforma and excel sheet were analyzed using statistical software SPSS version 21. Descriptive statistics summarized demographic and clinical variables.ResultsAmong the study participants, 75.75% had negative H. pylori in UBT, indicating successful eradication, and 24.29% were still positive and received second-line quadruple therapy. In situations where H. pylori was not eradicated, the likelihood of geographic fatal H. pylori strains that were also not eradicated using conventional methods was established. In more than two-thirds of the patients, an improvement in their symptoms was observed, and among their common complaints were bloating (61%) and heartburn (40%). A subset of the patients had comorbidities, such as diabetes and metabolic-associated steatohepatitis (MASLD), which were also noted.ConclusionThe 13C UBT is crucial and non-invasive test and is used to verify whether H. pylori has been eradicated after treatment. Since the efficacy of UBT has already been proven, it plays a significantly important role in cases of treatment failure, especially in regions resistant to strains. Regional variations in strain identification should be studied for more efficient treatment.Keywords: ¹³C urea breath test, H. pylori infection, Eradication therapy, Quadruple therapy, Antibiotic resistance Introduction Infection with Helicobacter pylori (H. pylori) is recognized as a causative factor of peptic ulcer disease, gastritis, and gastric malignancy in most parts of the world, highlighting the need to adopt more specific diagnostic and effective eradication regimens [1]. In this context, ¹³C Urea Breath Test (UBT) has become an extremely powerful, non-invasive tool in identifying active H. pylori infection and determining post-therapy cure. Its extraordinary sensitivity and specificity, which are consistently higher than 90%, make UBT a better alternative to most serological and invasive tests. The safety and high tolerability are contributing factors that make this test a preferable option among patients [2, 3]. In addition, accumulating data highlights the usefulness of UBT in guiding clinical decision-making, proving therapeutic accomplishment, and reducing the occurrence of extraneous repeat endoscopy [4, 5]. Despite the popularity of the test, there is still controversy as to the exact time frame in which upper gastrointestinal ultrasonography (UGU) should be performed after eradication therapy, at the same time as there is no consensus on the optimum duration of treatment regimens, with resultant implications on the accuracy of the test and consequently clinical outcome. That time of day when the ultrasonographic values are equal between out-of-the-question negative and negative values, so-called gray zone, frequently creates a current problem in diagnosis and may give a false impression to the practitioners regarding actual eradication status [6]. The study of 13C-UBT performance in the existing literature is limited to the cross-sectional comparison at a specific moment of diagnosis or against other diagnostic platforms [7, 8]. Cohort longitudinal studies, which examine treatment course through extended programs of eradication, have attracted less research, although they are essential for disentangling changes with time in the process of bacterial clearance. Considering that there are no standardized protocols for 13C-UBT regarding the optimal timing after administering therapy, future studies that determine the most appropriate test intervals are essential. The limitations are dealt with in the present study. The prospective design is consciously aimed at the longitudinal assessment of 13 C-UBT in an interventionally clear four months. Investigating the dynamics of bacterial clearance by comparing the UBT results obtained at standardized post-treatment time points is expected to provide the basis for empirical evidence, which, in turn, will inform evidence-based recommendations for the clinical decision-making process. The present study aims to define the efficiency of the 13 C UBT in validating the effective elimination of H. pylori following first-line treatment and post-antibiotic regimens. The geographic variation in therapeutic efficacy, especially among regions that harbor drug-resistant strains, still requires attention, and standardization of the timing of therapy and follow-up is imperative in enhancing the accuracy of diagnosis and clinical judgments. Materials and methods Aim The primary objective of the current observational study was to utilize the 13 C UBT in evaluating the effectiveness of second-line quadruple therapy in assessing treatment failure due to infection with resistant strains of H. pylori, particularly in the state of Odisha. Design This prospective clinical study was conducted between January 2025 and May 2025, aiming to determine the effectiveness of the 13 C UBT in detecting whether H. pylori is eradicated after administering the first line of treatment, followed by a confirmatory repeat 13 C UBT. Setting The study was conducted in two different centers, namely KIMS Super Speciality and Cancer Centre and Apollo Hospital, Bhubaneswar. The patients were recruited randomly, those who were treated with H. pylori positive through the Rapid urease test during the upper GI endoscopy procedure. Study population We included 70 patients who were H. pylori carriers, as determined by rapid urease breath test (RUT) during endoscopy. To ensure the successful eradication of H. pylori, follow-up testing with a UBT method is recommended at least 4 weeks after completion of antibiotic therapy [9]. This delay is crucial to avoid false-negative results, especially when using medications like proton pump inhibitors (PPIs)- based triple therapy (PCA regimen), which includes a PPI, clarithromycin, and amoxicillin or metronidazole, as per standard clinical guidelines [10]. Inclusion criteria Adult patients (≥ 18 years) with confirmed H. pylori infection prior to treatment. Completion of first-line eradication therapy (PCA regimen) within 1 to 2 months prior to UBT testing. Ability and willingness to comply with the study protocol and undergo ¹³C UBT. Exclusion criteria Patients who had received second-line or salvage therapy. Use of antibiotics, bismuth compounds, or proton pump inhibitors within 4 weeks prior to UBT. Known allergy to eradication drugs or contraindications to breath testing. Pregnancy or lactation, as well as severe comorbidities that limited study participation, were excluded from the study. Eradication therapy The selected 70 patients completed the PCA regimen as per treatment protocols, typically lasting up to 14 days. The PCA regimen refers to a triple therapy consisting of the combination of PPI, clarithromycin, and amoxicillin. This is the recommended first-line treatment for H. pylori infection. Compliance was assessed through patient interviews and a review of their medication. ¹³C Urea breath test Following completion of therapy and a 4-week washout period, patients were scheduled for the ¹³C UBT to confirm eradication status. The test was performed using a commercially available ¹³C UBT kit according to the instructions provided by the manufacturer. After an overnight fast, baseline breath samples were collected. Patients then ingested a capsule containing ¹³C-labeled urea, followed by the collection of breath samples at 30 min post-ingestion. The breath samples were analyzed using isotope ratio mass spectrometry or infrared spectrometry, and results were expressed as delta over baseline (DOB) values. A predefined cutoff value, as recommended by the test kit manufacturer and literature, was used to determine H. pylori infection status. The details of the UBT test and its result have been depicted (Fig. 1). Urease Breath Test for Helicobacter pylori Detection. The figure shows (a) the urease breath test instrument used to analyze exhaled breath samples, (b) a negative test result indicating the absence of H. pylori infection, and (c) a positive test result showing elevated labelled CO₂ levels, consistent with the presence of H. pylori Data collection and outcome measures Demographic data, clinical history, and details of prior eradication treatment were recorded. The primary outcome was the efficiency of ¹³C UBT in confirming H. pylori eradication post-therapy, measured by the proportion of patients with negative UBT results following treatment. Secondary outcomes included the correlation between the time elapsed since therapy completion and UBT results, as well as the assessment of any inconclusive or borderline results. Statistical analysis Data were analyzed using SPSS version 21. Descriptive statistics summarized demographic and clinical variables. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of ¹³C UBT were calculated using clinical and/or histological confirmation as the reference standard, where applicable. The impact of the time interval between therapy completion and UBT on test accuracy was assessed using appropriate tests (chi-square for categorical variables, t-test or ANOVA for continuous variables). A p-value < 0.05 was considered statistically significant. Ethical considerations The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Ethics Committee. The institutional ethical clearance was obtained from the Institutional Ethics Committee, Biomedical Research, Apollo Hospitals, Bhubaneswar, bearing Regd No. EC/NEW/INSTI/2022/OR/0205. The written informed consent was obtained from all participants prior to enrolment. Results The study included 70 participants with a mean age of 42.5 ± 12.7 years, ranging from 24 to 80 years, reflecting a broad age distribution among the adult participants. Males predominated, accounting for 64% (n = 45) of the cohort, while females comprised 36% (n = 25). The average weight was 66.5 ± 11.5 kg, with a range between 44 and 96 kg, and the mean height was 164 ± 8.0 cm, ranging from 144 to 178 cm. The mean BMI was 24.3 ± 3.5 kg/m², spanning from 19.03 to 36.2, indicating that most participants were within the normal to overweight range. Blood pressure measurements showed an average systolic pressure (SBP) of 125 ± 12.2 mmHg (range, 94–152 mmHg) and a diastolic pressure (DBP) of 79 ± 9.4 mmHg (range, 62–100 mmHg), indicating that most patients were normotensive at baseline (Table 1). Table 1Baseline demographic and clinical characteristics of study participantsVariableMean ± SDRange (Min – Max)Frequency (%)Age (years)42.5 ± 12.724–80GenderMale: 45 (64%)Female: 25 (36%)Weight (kg)66.5 ± 11.544–96Height (cm)164 ± 8.0144–178BMI (kg/m²)24.3 ± 3.519.03–36.2SBP (mmHg)125 ± 12.294–152DBP (mmHg)79 ± 9.462–100 Baseline demographic and clinical characteristics of study participants Male: 45 (64%) Female: 25 (36%) Among the 70 study participants, the most common gastrointestinal symptoms were bloating, reported by 61% (n = 43), followed by heartburn and early satiety, each affecting 40% (n = 28), and nausea and vomiting, which occurred in 23% (n = 16) of the patients. These symptoms reflect the typical clinical presentation of patients undergoing evaluation for H. pylori-related issues. Regarding comorbid conditions, 16% (n = 11) had diabetes mellitus, 11% (n = 8) were diagnosed with hypertension, and 4% (n = 3) had MASLD (fatty liver disease). Moreover, the comorbidities, including diabetes mellitus (16%), hypertension (11%), MASLD (4%), and other conditions such as thyroid disease, tuberculosis, coronary artery disease, hepatitis B, and chronic gastritis, all had p-values of < 0.0001, reflecting highly significant associations (Table 2). Additionally, 14% (n = 10) of patients presented with other comorbidities, including thyroid disorders, tuberculosis, coronary artery disease, hepatitis B, and chronic gastritis, highlighting the complexity of the clinical profile in this population. Table 2Symptom and comorbidity profile of study participantsSymptom/ConditionFrequency (n)Percentage (%)p-valuesNausea (Y)1623%< 0.0001Bloating (Y)4361%0.0558Heartburn (Y)2840%0.0943Early Satiety (Y)2840%0.0943Vomiting (Y)1623%< 0.0001Common Comorbidities< 0.0001 - Diabetes Mellitus (DM)1116%< 0.0001 - Hypertension (HTN)811%< 0.0001 - MASLD (Fatty Liver)34%< 0.0001 - Others (Thyroid, TB, CAD, Hepatitis B, Chronic Gastritis, etc.)1014%< 0.0001 Symptom and comorbidity profile of study participants All 70 patients included in the study tested positive for H. pylori infection using the Rapid Urease Test (RUT), confirming active infection at baseline. The clinical diagnosis, UGI endoscopy findings, and RUT results indicate that all 70 patients tested positive for H. pylori using the RUT, with a p-value of < 0.0001, showing a highly significant result. Among the common clinical diagnoses, 85% of patients were diagnosed with H. pylori gastritis, either with or without comorbidities such as MASLD, vitamin B12 deficiency, GERD, and HH, with a p-value of < 0.0001. MASLD was observed in 21% of patients, but the p-value of 0.79 suggests no significant difference from the expected distribution. GERD was found in 14% of patients, with a p-value of 0.29, indicating no significant deviation. Duodenal and gastric ulcers/erosions were present in 29% of patients, and other conditions like chronic pancreatitis and hepatitis B were seen in 21% of patients, with p-values of 0.11 and 0.79, respectively, suggesting no statistically significant difference for these conditions (Table 3). Duodenal and gastric ulcers or erosions were noted in 29% (n = 20), reflecting the common mucosal damage associated with H. pylori infection. Other less frequent diagnoses, including chronic pancreatitis, various vitamin deficiencies, colonic conditions, and hepatitis B, were observed in 21% (n = 15) of patients, underscoring the complex clinical context in this cohort. Table 3Clinical diagnosis, UGI endoscopy findings, and RUT resultsCommon Clinical DiagnosesFrequency (n = 70)Percentage (%)P-valueAll patients tested positive on RUT70100%< 0.0001 - H. pylori gastritis (with or without comorbidities like MASLD, Vitamin B12 deficiency, GERD, HH, etc.)6085%< 0.0001 - MASLD (fatty liver disease)1521%0.79 - GERD1014%0.29 - DUODENAL and gastric ulcers/erosions2029%0.11 - Other conditions (chronic pancreatitis, vitamin deficiencies, colonic conditions, hepatitis B)1521%0.79 Clinical diagnosis, UGI endoscopy findings, and RUT results The summary of UBT results, categorized by the timing of testing after eradication therapy, is outlined (Table 4). On average, there was a 50.4 ± 14.4-day interval between the completion of the eradication regimen and the administration of the ¹³C Urea Breath Test, with a range from 32 to 94 days, ensuring an appropriate washout period to reduce the likelihood of false-positive results. Patients fasted for an average of 5.4 ± 1.5 h prior to testing, with the fasting duration ranging from 3 to 9 h, in accordance with recommended pre-test guidelines. Among the study population, 75.71% (n = 53) had negative UBT results, indicating successful eradication of H. pylori, while 24.29% (n = 17) showed positive results, suggesting treatment failure. The p-value for the eradication success was 0.000017, indicating a highly significant result in favour of the success rate of therapy (Table 4). These results emphasize the effectiveness of first-line eradication therapy in this clinical setting and confirm the value of UBT as a reliable, non-invasive method for assessing eradication success. Table 4UBT Results summary and eradication success by UBT timing groupVariableMean ± SDRange (Min – Max)Duration between stopping regimen & UBT (days)50.4 ± 14.432–94Duration of fasting before UBT (hours)5.4 ± 1.53–9UBT ResultFrequency (n)Percentage (%)p-valueNegative (Eradication Success)5375.71%0.000017Positive (Treatment Failure)1724.29% UBT Results summary and eradication success by UBT timing group Out of the total 17 patients who initially tested positive for H. pylori infection in the UBT, all were administered quadruple therapy. After completing the therapy, a confirmatory UBT test was conducted, which revealed that 2 patients (11.76%) still tested positive, indicating treatment failure. However, 4 patients (23.53%) reported feeling better, 5 patients (29.41%) experienced mild discomfort, and 6 patients (35.29%) achieved remission of all symptoms, indicating successful eradication of the infection. The p-values for treatment failure, better outcomes, mild discomfort, and remission were all greater than 0.05, indicating no significant difference from the expected distribution. However, the p-value for eradication success was 0.023, suggesting a significant deviation and indicating that the treatment success in achieving full eradication was limited (Table 5). No patients showed negative results in the confirmatory test while still experiencing symptoms, highlighting the overall effectiveness of the treatment regimen in most cases. Table 5Post-Treatment Outcomes Following Quadruple Therapy in Confirmed Positive UBT PatientsPost-UBT Treatment RegimenPost-Treatment ObservationFrequency (n = 17)Percentage (%)p-valueQTPositive (Treatment Failure)211.76%0.310QTBetter423.53%0.758QTMild Discomfort529.41%0.894QTRemission of All Symptoms635.29%0.962QTNegative (Eradication Success)00%0.023QT Quadruple Therapy Post-Treatment Outcomes Following Quadruple Therapy in Confirmed Positive UBT Patients QT Quadruple Therapy Discussion In this prospective study of 70 patients undergoing evaluation for Helicobacter pylori eradication, we found a successful eradication rate of 75.71% (53/70) based on negative ¹³C Urea Breath Test (UBT) results performed at a mean of 50.4 ± 14.4 days post-therapy. Conversely, 24.29% (17/70) of patients had persistently positive UBT, indicating treatment failure. These results are consistent with those reported in previous studies, validating the effectiveness of the first-line therapy utilized in our cohort. Said and El-Nasser (2024) observed an eradication success of 85.2% in adult dyspeptic patients when UBT was conducted 4–6 weeks after therapy completion, closely paralleling our 75.71% success rate [11]. Similarly, another study reported that the meta-analytic eradication rate was approximately 83.5% in Asian populations, supporting the consistency of our findings within a broader demographic context [12]. The treatment failure rate of 24.29% in our study aligns with meta-analyses and clinical trials reporting failure rates ranging from 14% to 18% despite adherence to guideline-based regimens [13]. This highlights that despite improvements in treatment protocols, a significant minority of patients require retreatment. The timing of UBT at approximately 50 days post-therapy aligns with optimal testing windows that minimize false positives due to residual urease activity, thereby enhancing the reliability of our results [14]. Among patients with persistent infection, the second-line quadruple therapy (QT) regimen was the predominant treatment, resulting in complete symptom remission in 36.4%, symptomatic improvement in 31.8%, and mild discomfort reported by 31.8%. In contrast, 81% of patients with negative UBT who did not undergo further treatment reported symptom improvement, and 12.8% experienced complete symptom remission, underscoring the high negative predictive value of UBT for guiding clinical management [15]. The demographic profile of our cohort, with a mean age of 42.5 ± 12.7 years and a male predominance of 64%, is consistent with prior studies, which reported a mean age of 43.1 years and 62% male predominance [11]. The mean BMI of 24.3 ± 3.5 kg/m² in our participants aligns with other findings, further contextualizing the typical nutritional status in affected populations [16]. Symptom profiles, including bloating (61%), heartburn (40%), and early satiety (40%), were like those described in other cohorts, notably those who found bloating in 58% and heartburn in 43% of patients, confirming the reproducibility of these common gastrointestinal manifestations [11]. The prevalence of comorbidities such as diabetes mellitus (16%) and MASLD (4%) also reflects the complex clinical backgrounds frequently reported in H. pylori-infected patients [17]. All patients initially tested positive on Rapid Urease Test (RUT), affirming active infection and the appropriateness of our inclusion criteria. The predominance of H. pylori gastritis (85%) and the notable presence of duodenal and gastric ulcers/erosions (29%) correspond with epidemiological data reported, validating the clinical diagnoses within this population [1, 18]. Conclusion ¹³C UBT is a reliable, non-invasive method for confirming H. pylori eradication success after both first-line and second-line therapy. In our cohort, a successful eradication rate of 75.71% was observed, which aligns with global data and emphasizes the critical role of UBT in guiding clinical decisions. The study emphasizes the importance of timely post-treatment testing, ideally performed around 7 weeks after therapy, and strict adherence to fasting protocols to minimize false results and ensure diagnostic accuracy. While the study offers valuable insights into treatment outcomes in Odisha, we recognize the limitation of a small cohort (n = 70) recruited from a single clinical center. The findings point to a potential regional variation in the persistence of infection caused by resistant H. pylori strains. Future, multi-center studies with larger, more diverse cohorts are needed to confirm the presence of regional variations and to improve our understanding of H. pylori resistance patterns across different populations. The current study highlights the importance of standardizing the timing of UBT testing and preparation protocols to improve the accuracy of H. pylori eradication assessments. Implementing evidence-based practices into routine clinical workflows will help detect treatment failures early, enabling prompt and effective retreatment. This approach not only improves patient outcomes but also contributes to combating antibiotic resistance by minimizing unnecessary prolonged therapies. In conclusion, adopting standardized and reliable diagnostic methods, such as the ¹³C UBT, is vital for improving the management of H. pylori infections, preventing peptic ulcers, and reducing the global risk of gastric cancer. Our findings are insightful, the relatively small cohort of 70 patients from a single clinical center may limit the generalizability of these results to broader, more diverse populations. Further research is essential to substantiate these findings and enhance the global understanding of H. pylori eradication and resistance. Acknowledgements Not applicable. Abbreviations ¹³C-urea breath test Helicobacter pylori Metabolic Dysfunction-Associated Steatotic Liver Disease Upper gastrointestinal ultrasonography Gastrointestinal endoscopy Rapid urease test Proton pump inhibitor Potassium-Competitive Acid Blocker Delta over baseline Positive predictive value Negative predictive value Quadruple therapy Authors’ contributions (I) Conception and design: D.M. and K.U. (II) Administrative support: M.K.S. (III) Provision of study materials or patients: S.B.P, P.S.J., and A.D. (IV) Collection and assembly of data: S.B.P. and K.U. (V) Data analysis and interpretation: D.M. and S.B.P. (VI) Manuscript writing: D.M. and K.U. (VII) Final approval of manuscript: all authors. Funding There was no external or internal funding associated in this study. Data availability The datasets used and analysed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Ethics Committee. The institutional ethical clearance was obtained from the Institutional Ethics Committee, Biomedical Research, Apollo Hospitals, Bhubaneswar, bearing Regd No. EC/NEW/INSTI/2022/OR/0205. The written informed consent was obtained from all participants prior to enrolment. Consent for publication The study participants provided written informed consent for the use of anonymized imaging data and clinical characteristics in this publication, ensuring that their personal information and medical history remain confidential and protected throughout the study process. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The datasets used and analysed during the current study are available from the corresponding author on reasonable request.